5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure


 

NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherapy and PARP Inhibitors in TNBC & Trastuzumab Biosimilars in HER2 BC

266 views
September 13, 2019
Comments 0
Login to view comments. Click here to Login